Tryptamicidin: Phase I data

An open-label, dose-escalation, U.S. and Spanish Phase I trial in 31 patients with refractory solid tumors showed that IV infusions of PM01183 every 3 weeks were well tolerated up to 5 mg/m 2, which w...